Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.
9 findings from 1 review
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes40 to 60 months · Skin toxicity (lapatinib, all grades)RR 2.02 [1.23, 3.32]1 study · 67 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes40 to 60 months · Gastrointestinal complaints (gefitinib, all grades)RR 1.04 [0.98, 1.11]1 study · 226 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes40 to 60 months · Gastrointestinal complaints (lapatinib, all grades)RR 15.53 [2.18, 110.55]1 study · 67 participantsGRADE not reported
Show 6 more findings
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes40 to 60 months · Skin toxicity (erlotinib, all grades)RR 6.57 [3.60, 12.00]1 study · 191 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes40 to 60 months · Mucositis (grades >=3)RR 1.22 [0.96, 1.56]2 studies · 286 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes40 to 60 months · Mucositis (all grades)RR 1.03 [0.94, 1.11]2 studies · 286 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes40 to 60 months · Skin toxicity (gefitinib, all grades)RR 1.03 [0.82, 1.28]2 studies · 286 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes40 to 60 months · Gastrointestinal complaints (grades >=3, pooled)RR 1.11 [0.83, 1.49]3 studies · 484 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes40 to 60 months · Skin toxicity (grades >=3, pooled)RR 1.25 [0.54, 2.88]4 studies · 544 participantsGRADE not reported